Fig. 1 · Structure

Documents & Downloads

Cinchonidine

Cat. No. A10220 CAS 485-71-2
Cinchonidine is an alkaloid used in asymmetric synthesis in organic chemistry. It is a stereoisomer and pseudo-enantiomer of cinchonine.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Plasmodium  

Cellular Effect

Cell Line Activity Value Description Reference
WI-38 IC50 > 20 μg/mL Cytotoxicity against human WI38 cells by MTT assay [PMID: 23816880]
WI-38 IC50 > 68.03 μM Cytotoxicity against human WI38 cells by MTT assay [PMID: 26063305]

Cinchonidine Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Cinchonidine from 2 published references. In vitro models include serum-deprived mouse C2C12 myoblast cells.

Cinchonidine In Vitro Studies

In insulin-stimulated C2C12 myoblasts, cinchonidine (50 μM) reduced IRS-1 and AKT phosphorylation during a 15-minute exposure, while S6K and GSK3 phosphorylation were reported unaffected. This response is specific to the tested cellular context and does not establish direct binding to these proteins. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Context-dependent suppression of insulin-stimulated IRS-1/AKT signaling

Cell-based study · Serum-deprived mouse C2C12 myoblast cells [1]

At 50 μM, cinchonidine reduced insulin-stimulated IRS-1 and AKT phosphorylation. S6K and GSK3 phosphorylation were reported unaffected under the same conditions. This experiment does not identify a direct molecular binding target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IRS-1 Ser318 and AKT Ser473 phosphorylation relative to total proteinQualitative direction Reduced relative to insulin/vehicle condition[1]
S6K and GSK3 phosphorylationReported limiting result Not affected by cinchonidine under the tested conditions[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM cinchonidine; insulin 5 ng/mL.
Exposure duration
15 min insulin exposure in medium containing cinchonidine, after 16 h serum deprivation.
Method
Immunoblot of phosphorylated and total IRS-1/AKT and related downstream signaling proteins.
Vehicle
Vehicle control reported; chemical composition not specified in the read methods.
Co-treatment
Insulin stimulation; untreated, insulin/vehicle and insulin/CD conditions.
Reported limits
Replicate count for Figure 3 and vehicle composition not specified in the read methods/caption.
Methods and source locations

Compound reported in the paper: Cinchonidine; Compound label in the paper: CD

Cell- and stimulus-specific signaling response.

Figure 3A–B and caption; Materials and Methods, Western blot analysis; Results, CD inactivates insulin signaling pathway in myogenic differentiation

IRS-1 Ser318 and AKT Ser473 phosphorylation relative to total protein: Immunoblot and normalized densitometry; Figure 3A. — Figure 3A–B and caption; Materials and Methods, Western blot analysis; Results, CD inactivates insulin signaling pathway in myogenic differentiation

S6K and GSK3 phosphorylation: Immunoblot; Figure 3B. — Figure 3A–B and caption; Materials and Methods, Western blot analysis; Results, CD inactivates insulin signaling pathway in myogenic differentiation

Cinchonidine In Vivo Studies

In male mice with tibialis-anterior muscle injury, cinchonidine administered in drinking water at a reported 25 mg/kg for six days was associated with smaller regenerating muscle fiber diameters. The authors reported no significant changes in liver histology or measured blood biochemistry over this course; these observations do not establish general safety. [1]

In a male mouse MCAO/reperfusion model, cinchonidine reduced acute infarct volume when administered at 5 or 10 mg/kg before ischemia or at 10 mg/kg one hour after reperfusion. The 10 mg/kg regimens also reduced brain edema at 24 hours. The study did not establish long-term benefit, pharmacokinetics or brain penetration. [2]

Reduced regeneration-associated muscle fiber diameter in injured mice

Animal study · BaCl2-injured tibialis anterior muscle of eight-week-old male C57BL/6 mice [1]

Following cinchonidine exposure, histology showed a shift toward smaller regenerating fiber diameters. The selected data assess muscle regeneration morphology; they do not establish a muscle-strength effect in humans. Liver histology and measured blood biochemistry showed no significant differences according to the authors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Diameter distribution of regenerating tibialis-anterior muscle fibersQualitative histological shift Smaller fiber diameters with CD[1]
Liver histopathology and ALT, AST, ALP, glucose, total cholesterol and BUNReported comparison No significant differences reported[1]

Conditions shared by the study groups

Route
Drinking water
Treatment course
Started the day after tibialis-anterior injury; treatment for 6 days
Vehicle
Drinking water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cinchonidine after muscle injury
25 mg/kg
Injured control/vehicle groupRegenerating muscle fibers shifted toward smaller diameters. The authors reported no significant difference in liver histology or blood biochemistry.[1]
Cinchonidine after muscle injury
Model: Eight-week-old male C57BL/6 mice; four different mice per group in Figure 5B
Reported limits: Water intake, achieved exposure and dosing frequency were not specified; the reported dose is not rewritten as mg/kg/day.
Methods and source locations

Compound reported in the paper: Cinchonidine; Compound label in the paper: CD

Injury-model histology and limited toxicity observations only.

Figure 5A–D/caption; Materials and Methods, Animals; Results, CD inhibits satellite cells activity and lowers muscle regeneration capacity

Diameter distribution of regenerating tibialis-anterior muscle fibers: H&E histology and diameter-bin distribution; four different mice per group. Figure 5B has no exact summary diameter estimate or inferential annotation. — Figure 5A–D/caption; Materials and Methods, Animals; Results, CD inhibits satellite cells activity and lowers muscle regeneration capacity

Liver histopathology and ALT, AST, ALP, glucose, total cholesterol and BUN: Figure 5C–D; no numeric assay values estimated from bars. This is not a comprehensive safety evaluation. — Figure 5A–D/caption; Materials and Methods, Animals; Results, CD inhibits satellite cells activity and lowers muscle regeneration capacity

Cinchonidine after muscle injury · Figure 5A–D/caption; Materials and Methods, Animals; Results, CD inhibits satellite cells activity and lowers muscle regeneration capacity

Reduced acute ischemic lesion burden in male mice

Animal study · Male C57BL/6 mice, 6–8 weeks, transient MCAO/reperfusion; separate acute histology cohort [2]

Cinchonidine reduced infarct volume at 24 h after reperfusion. At 10 mg/kg, both pre-treatment and post-treatment also reduced edema. Results remain limited to acute injury in male mice; pharmacokinetics, brain penetration and long-term benefit were not established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Edema-corrected infarct volume as percentage of contralateral hemisphereQualitative direction Lower in all three cinchonidine groups than vehicle-treated MCAO[2]
Brain edema ratioQualitative direction and comparison limits Lower with 10 mg/kg pre- or post-treatment; no significance mark for pre-treatment 5 mg/kg versus vehicle[2]

Conditions shared by the study groups

Route
Intraperitoneal
Vehicle
PEG400:DMSO, 9:1 (v/v); 100 μL/mouse
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pre-treatment 5 mg/kg
5 mg/kg
Vehicle-treated MCAO; sham also includedInfarct volume was lower than vehicle with a significance mark. Edema was numerically lower; Figure 1D does not mark this comparison as significant.[2]
Pre-treatment 10 mg/kg
10 mg/kg
Vehicle-treated MCAO; sham also includedInfarct volume and edema were lower than vehicle with significance marks.[2]
Post-treatment 10 mg/kg
10 mg/kg
Vehicle-treated MCAO; sham also includedInfarct volume and edema were lower than vehicle with significance marks.[2]
Pre-treatment 5 mg/kg
Model: Male C57BL/6 mice, 6–8 weeks; acute histology cohort, n = 8/group
Treatment course: 1 h before MCAO
Reported limits: One timed administration is described; no repeated dosing schedule is specified.
Pre-treatment 10 mg/kg
Model: Male C57BL/6 mice, 6–8 weeks; acute histology cohort, n = 8/group
Treatment course: 1 h before MCAO
Reported limits: One timed administration is described; no repeated dosing schedule is specified.
Post-treatment 10 mg/kg
Model: Male C57BL/6 mice, 6–8 weeks; acute histology cohort, n = 8/group
Treatment course: 1 h after reperfusion
Reported limits: One timed administration is described; no repeated dosing schedule is specified.
Methods and source locations

Compound reported in the paper: Cinchonidine; Compound label in the paper: CD

Acute histological outcome; not clinical efficacy or demonstrated BBB penetration.

Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations

Edema-corrected infarct volume as percentage of contralateral hemisphere: TTC histology at 24 h after reperfusion; mean ± SEM, n = 8/group. No exact bar values inferred. — Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations

Brain edema ratio: Figure 1D; mean ± SEM, n = 8/group. No exact bar values inferred. — Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations

Pre-treatment 5 mg/kg · Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations

Pre-treatment 10 mg/kg · Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations

Post-treatment 10 mg/kg · Figure 1A–D/caption; sections 2.2–2.4 and 3.1; Discussion limitations

Specifications

Manufacturer Adooq Bioscience
CAS Number 485-71-2
Formula C19H22N2O
Molecular Weight 294.4
Synonyms L-Cinchonidine; alpha-Quinidine
SMILES
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@@H](C3=CC=NC4=CC=CC=C34)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 51 mg/mL (173.24 mM)
Water Insoluble
Ethanol 51 mg/mL (173.24 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cinchonidine Research References

  1. [1] Byun MR, Joo SH, Jung YS, et al. Cinchonidine induces muscle weakness by inhibiting insulin-mediated IRS-1-AKT signaling pathway Journal of microbiology (Seoul, Korea) (2025). PMID: 41486936 DOI: 10.71150/jm.2511017 Source material
  2. [2] Lu KJ, Hsu CY, Jayakumar T, et al. Cinchonidine, a Natural Quinoline Alkaloid, Attenuates Ischemic Neurovascular Injury Through Blood-Brain Barrier Preservation Biomedicines (2026). PMID: 42511917 DOI: 10.3390/biomedicines14071442 Source material

Added to your cart

View Cart Checkout
Loading...